The Long Run with Luke Timmerman
Ep162: Sean McClain on AI for Biologic Drug Discovery
Jul 16, 2024
Sean McClain, CEO of Absci, discusses using AI to speed up biologic drug discovery. Topics include the upcoming clinical testing of an antibody drug for inflammatory bowel disease in 2025, integrating AI into drug discovery, the creative aspects of biologic drug discovery, engineering E. coli for biologic therapies, evolving business models in biologic drug discovery, unexpected discoveries in drug compound affinity, and revolutionizing drug discovery with AI-generated biologics.
01:05:59
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Absci uses AI to accelerate biologic drug candidate discovery.
- AI-driven platform optimizes antibody design for challenging diseases.
Deep dives
Sean McLean's Journey from Startup to Biotech Advancements
Sean McLean is the founder of AvSci, a biotech company specializing in antibody drug discovery. AvSci, initially a scrappy garage biotech, leveraged E. coli assays for testing antibodies quickly and cost-effectively. Embracing AI, the company aimed to accelerate biologic drug candidate discovery. With McLean as CEO, AvSci has raised over $530 million, preparing to advance their antibody drug candidate for inflammatory bowel disease into clinical trials in 2025.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
